分裂情感性精神障碍

Cheniaux E, Landeira-Fernandez J, Versiani M. The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology. 2009;42:293-298.

• 摘要

Jäger M, Haack S, Becker T, et al. Schizoaffective disorder: an ongoing challenge for psychiatric nosology. Eur Psychiatry. 2011;26:159-165.

• 摘要

Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1089-109.

• 全文
• 摘要

Lencz T, Lipsky RH, DeRosse P, et al. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry. 2009;194:313-318.

• 全文
• 摘要

Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999 Apr;156(4):544-9.

• 摘要

Turner DT, van der Gaag M, Karyotaki E, et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014 May;171(5):523-38.

• 摘要

Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry. 2013;203:172-178.

• 全文
• 摘要

Harrow M, Grossman LS, Herbener ES, et al. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000;177:421-426.

• 全文
• 摘要

National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. October 2016 [internet publication].

• 全文

1.  American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

2.  World Health Organization. The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. 1993 (updated for 2016) [internet publication].

• 全文

3.  Cheniaux E, Landeira-Fernandez J, Versiani M. The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology. 2009;42:293-298.

• 摘要

4.  Jäger M, Haack S, Becker T, et al. Schizoaffective disorder: an ongoing challenge for psychiatric nosology. Eur Psychiatry. 2011;26:159-165.

• 摘要

5.  Marneros A, Deister A, Rohde A. Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatr Scand. 1990 Nov;82(5):352-8.

• 摘要

6.  Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1089-109.

• 全文
• 摘要

7.  Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007 Jan;64(1):19-28.

• 全文
• 摘要

8.  Scully PJ, Owens JM, Kinsella A, et al. Schizophrenia, schizoaffective and bipolar disorder within an epidemiologically complete, homogeneous population in rural Ireland: small area variation in rate. Schizophr Res. 2004 Apr 1;67(2-3):143-55.

• 摘要

9.  Azorin JM, Kaladjian A, Fakra E. Current issues on schizoaffective disorder [in French]. Encephale. 2005 May-Jun;31(3):359-6.

• 摘要

10.  Hamshere ML, Bennett P, Williams N, et al. Genomewide linkage scan in schizoaffective disorder: significant evidence for linkage at 1q42 close to DISC1, and suggestive evidence at 22q11 and 19p13. Arch Gen Psychiatry. 2005;62:1081-1088.

• 全文
• 摘要

11.  Lencz T, Lipsky RH, DeRosse P, et al. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry. 2009;194:313-318.

• 全文
• 摘要

12.  Meltzer HY, Arora RC, Metz J. Biological studies of schizoaffective disorders. Schizophr Bull. 1984;10(1):49-70.

• 摘要

13.  Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict. 2006 Sep-Oct;15(5):345-55.

• 摘要

14.  Caton CL, Samet S, Hasin DS. When acute-stage psychosis and substance use co-occur: differentiating substance-induced and primary psychotic disorders. J Psychiatr Pract. 2000 Sep;6(5):256-66.

• 摘要

15.  Gregg L, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis. Clin Psychol Rev. 2007 May;27(4):494-510.

• 摘要

16.  Sipos A, Rasmussen F, Harrison G, et al. Paternal age and schizophrenia: a population based cohort study. BMJ. 2004 Nov 6;329(7474):1070.

• 全文
• 摘要

17.  Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull. 2003;29(4):671-92.

• 摘要

18.  Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma - a critical review. Schizophr Bull. 2007 Jan;33(1):3-10.

• 全文
• 摘要

19.  American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004 Feb;65(2):267-72.

• 摘要

20.  Dazzan P, Murray RM. Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry. 2002;43:s50-s57.

• 摘要

21.  Tosato S, Dazzan P. The psychopathology of schizophrenia and the presence of neurological soft signs: a review. Curr Opin Psychiatry. 2005;18:285-288.

• 摘要

22.  Rector NA, Beck AT, Stolar N. The negative symptoms of schizophrenia: a cognitive perspective. Can J Psychiatry. 2005;50:247-257.

• 摘要

23.  Bradizza CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. J Subst Abuse Treat. 1997 Mar-Apr;14(2):103-11.

• 摘要

24.  Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry. 2002 Aug;47(6):518-26.

• 摘要

25.  Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-70.

• 摘要

26.  Klosterkotter J, Ebel H, Schultze-Lutter F, et al. Diagnostic validity of basic symptoms. Eur Arch Psychiatry Clin Neurosci. 1996;246(3):147-54.

• 摘要

27.  Klosterkötter J, Hellmich M, Steinmeyer EM, et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001 Feb;58(2):158-64.

• 全文
• 摘要

28.  Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172(33):14-20.

• 摘要

29.  Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003 Mar 1;60(1):21-32.

• 摘要

30.  Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002 May;159(5):863-5.

• 摘要

31.  Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet. 1995 Sep 23;346(8978):820-5.

• 摘要

32.  Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325-51.

• 全文
• 摘要

33.  Peterson D, Olson G. First admitted schizophrenics in drug era. Arch Gen Psychiatry. 1964 Aug;11:137-44.

• 摘要

34.  Loebel AD, Lieberman JA, Alvir JM, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992 Sep;149(9):1183-8.

• 摘要

35.  Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull. 1996;22(2):241-56.

• 摘要

36.  Malla AK, Norman RM, Manchanda R, et al. One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophr Res. 2002 Apr 1;54(3):231-42.

• 摘要

37.  Malla AK, Norman RM, Manchanda R, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv. 2002 Apr;53(4):458-63.

• 摘要

38.  Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001 Apr;31(3):381-400.

• 摘要

39.  McGrath J, Emmerson WB. Fortnightly review. Treatment of schizophrenia. BMJ. 1999 Oct 16;319(7216):1045-8.

• 全文
• 摘要

40.  Harding CM. Course types in schizophrenia: an analysis of European and American studies. Schizophr Bull. 1988;14(4):633-43.

• 摘要

41.  Beels CC. Social support and schizophrenia. Schizophr Bull. 1981;7(1):58-72.

• 全文
• 摘要

42.  Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull. 1980;6(4):606-18.

• 摘要

43.  McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999 Oct 1;46(7):899-907.

• 摘要

44.  Larsen TK, Moe LC, Vibe-Hansen L, et al. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res. 2000 Sep 29;45(1-2):1-9.

• 摘要

45.  Larsen TK, McGlashan TH, Johannessen JO, et al. Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment. Am J Psychiatry. 2001 Nov;158(11):1917-9.

• 摘要

46.  Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003 Jan;33(1):97-110.

• 摘要

47.  Craig TJ, Bromet EJ, Fennig S, et al. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry. 2000 Jan;157(1):60-6.

• 摘要

48.  Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999 Apr;156(4):544-9.

• 摘要

49.  Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999 Mar;56(3):241-7.

• 全文
• 摘要

50.  Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994 Oct;51(10):826-36.

• 摘要

51.  Peuskens J. Good medical practice in antipsychotic pharmacotherapy. Int Clin Psychopharmacol. 1998 Mar;13(suppl 3):S35-41.

• 摘要

52.  Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999;60(suppl 10):20-30.

• 摘要

53.  Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010 Jan;36(1):94-103.

• 全文
• 摘要

54.  Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013 Sep 14;382(9896):951-62.

• 全文
• 摘要

55.  Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654.

• 全文
• 摘要

56.  Leucht S, Helfer B, Dold M, et al. Lithium for schizophrenia. Cochrane Database Syst Rev. 2015;(10):CD003834.

• 全文
• 摘要

57.  European Medicines Agency. New measures to avoid valproate exposure in pregnancy endorsed. 23 March 2018 [internet publication].

• 全文

58.  Gillies D, Sampson S, Beck A, et al. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2013;(9):CD003079.

• 全文
• 摘要

59.  Cottraux J, Note ID, Cungi C, et al. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry. 1995 Nov;167(5):635-41.

• 摘要

60.  Bouvard M, Mollard E, Guerin J, et al. Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychother Psychosom. 1997;66(1):27-32.

• 摘要

61.  Anaya C, Martinez Aran A, Ayuso-Mateos JL, et al. A systematic review of cognitive remediation for schizo-affective and affective disorders. J Affect Disord. 2012 Dec 15;142(1-3):13-21.

• 摘要

62.  Hoffmann H, Jackel D, Glauser S, et al. Long-term effectiveness of supported employment: 5-year follow-up of a randomized controlled trial. Am J Psychiatry. 2014 Nov 1;171(11):1183-90.

• 全文
• 摘要

63.  McGurk SR, Mueser KT, Xie H, et al. Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry. 2015 Sep 1;172(9):852-61.

• 摘要

64.  Dieterich M, Irving CB, Bergman H, et al. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2017;(1):CD007906.

• 全文
• 摘要

65.  Katschnig H. Rehabilitation in schizophrenia; guidelines for including psychosocial measures [in German]. Wien Med Wochenschr. 1998;148(11-12):273-80.

• 摘要

66.  Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7.

• 摘要

67.  Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003 Sep;9(5):344-53.

• 摘要

68.  Bauer-Staeb C, Jörgensen L, Lewis G, et al. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry. 2017 Sep;4(9):685-93.

• 全文
• 摘要

69.  Turner DT, van der Gaag M, Karyotaki E, et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014 May;171(5):523-38.

• 摘要

70.  Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014 Jan;204(1):20-9.

• 摘要

71.  Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012;2012:407171.

• 全文
• 摘要

72.  Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol. 2012;22:165-182.

• 摘要

73.  Choi KH, Wykes T, Kurtz MM. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry. 2013;203:172-178.

• 全文
• 摘要

74.  Harrow M, Grossman LS, Herbener ES, et al. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000;177:421-426.

• 全文
• 摘要

75.  Jager M, Bottlender R, Strauss A, et al. Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatr Scand. 2004;109:30-37.

• 摘要

76.  Torniainen M, Suvisaari J, Partonen T, et al. Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics. J Nerv Ment Dis. 2012;200:316-322.

• 摘要

77.  Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry. 2005;66(suppl 6):5-10.

• 摘要

78.  Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005 Jul;187:9-20.

• 全文
• 摘要

79.  Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.

• 全文
• 摘要

80.  Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci. 2001 Apr;932:44-58.

• 摘要

81.  Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253.

• 全文
• 摘要

82.  Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep;58(9):1379-82.

• 摘要

83.  Gray R, Gournay K. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs. 2000 Jun;7(3):205-11.

• 摘要

84.  Velamoor VR, Swamy GN, Parmar RS, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry. 1995 Nov;40(9):545-50.

• 摘要

85.  Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003 Jan;28(suppl 1):83-96.

• 摘要

86.  Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629.

• 全文
• 摘要

87.  Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004 Dec 1;71(2-3):195-212.

• 摘要

88.  Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-7.

• 摘要

89.  Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov;158(11):1774-82.

• 摘要

90.  Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry. 1998;59(suppl 12):17-22.

• 摘要

91.  National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. October 2016 [internet publication].

• 全文

92.  Cimo A, Stergiopoulos E, Cheng C, et al. Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review. BMC Psychiatry. 2012 Mar 23;12:24.

• 全文
• 摘要